Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
Johnson and Johnson
Covington
Baxter
McKinsey
Accenture
US Army
Colorcon

Generated: April 22, 2018

DrugPatentWatch Database Preview

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% Drug Profile

« Back to Dashboard

When do Heparin Sodium 12,500 Units In Sodium Chloride 0.9% patents expire, and when can generic versions of Heparin Sodium 12,500 Units In Sodium Chloride 0.9% launch?

Heparin Sodium 12,500 Units In Sodium Chloride 0.9% is a drug marketed by Hospira and is included in two NDAs.

The generic ingredient in HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% is heparin sodium. There are seventy-seven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
Summary for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
Drug patent expirations by year for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
Pharmacology for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

US Patents and Regulatory Information for HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% heparin sodium INJECTABLE;INJECTION 018911-005 Jan 30, 1985 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hospira HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% heparin sodium INJECTABLE;INJECTION 018916-003 Jan 31, 1984 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Baxter
Boehringer Ingelheim
QuintilesIMS
Citi
Johnson and Johnson
Queensland Health
Cipla
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.